NSC95397|NSC-95397|CAS 93718-83-3|DC Chemicals

Cas No.:	93718-83-3
Chemical Name:	2,3-bis[(2-Hydroxyethyl)thiol]-1,4-naphthoquinone
Synonyms:	NSC-95397;NSC 95397
SMILES:	C1=CC=C2C(=C1)C(=O)C(=C(C2=O)SCCO)SCCO
Formula:	C₁₄H₁₄O₄S₂
M.Wt:	310.38
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

NSC 95397 is an inhibitor for dual-specificity phosphatases, including mitogen-activated protein kinase phosphatase-1 (MKP-1). NSC 95397 suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway[1].

In Vitro:

NSC 95397 (0, 10, and 20 µM; 24 hour) decreases the cell viability of three colon cancer cell lines SW480, SW620, and DLD-1 in a concentration-dependent manner[1]. NSC 95397(10 μM; 24 hour) upregulates p21 while downregulates CDK4 and CDK6 were d in all three colon cancer cell lines SW480, SW620, and DLD-1 cells[1]. NSC 95397 (10 μM; 24 hour) reduces the phosphorylation of retinoblastoma protein (Rb) on Ser795 and Ser807/811[1]. NSC 95397 (20 μM; 24 hours) significantly increases cleaved caspase-9, -3, -7 and PARP levels[1]. NSC 95397 (10 μM; 6 hours) enhances the phosphorylation of its downstream ERK1/2 at Thr202/Tyr 204[1]. Cell Viability Assay[1] Cell Line: Human colon cancer cell lines, SW480, SW620, and DLD-1 Concentration: 0, 10, and 20 µM Incubation Time: 24 hours Result: The IC50 values of NSC 95397 for the cell growth of SW480, SW620, and DLD-1 cells were 9.9, 14.1 and 18.6 μM, respectively. Western Blot Analysis[1] Cell Line: SW480, SW620, and DLD-1 cells Concentration: 10 μM Incubation Time: 24 hours Result: p21 was upregulated while CDK4 and CDK6 were downregulated. Rduced the phosphorylation of Rb on Ser795 and Ser807/811

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC73792	NSC74429	NSC74429 is a CNS-active, small molecule PHLPP inhibitor with IC50 of <5 uM, shows neuroprotective activity in primary rat cortical neurons in STS assay.
DC50265	GDC-1971	GDC-1971 showed outstanding potency in biochemical and cell models, and it had a predicted human PK profile that suggested it would achieve target engagement at reasonable doses. GDC-1971 showed an IC50 below the limit of detection of the assay (≪0.001 μM), while that IC50 shifted to 0.17 μM in the same biochemical assay with the constitutively active E76K SHP2 mutant.
DC47388	PROTAC SHP2 degrader-1	PROTAC SHP2 degrader-1 is a potent and effective SHP2 degrader. PROTAC SHP2 degrader-1 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins and is also neddylation- and proteasome-dependent.
DC47165	CDC25B-IN-2	CDC25B-IN-2 is a potent cdc25B inhibitor.
DC39105	SC-43	SC-43, a sorafenib derivative, is an agonist of Src-homology protein tyrosine phosphatase-1 (SHP-1/PTPN6) and reduces liver fibrosis. SC-43 reduces p-STAT3 and induces apoptosis with anti-tumor activity.
DC28481	(E/Z)-BCI(DUSP6 inhibitor)	(E/Z)-BCI (NSC 150117) is a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory activities. (E/Z)-BCI attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting the NF-κB pathway.
DC11528	Razuprotafib	Razuprotafib is a potent protein tyrosine phosphatase β (HPTPβ) inhibitor..
DC11638	BCI(NSC 150117)	BCI is A small-molecule, allosteric inhibitor of DUSP6 (dual-specificity phosphatase 6) with IC50 of 12.3 uM; also inhibits human DUSP1 with IC50 of 11.5 uM; suppresses the ERK-induced activation of Dusp6 and regulates heart size in zebrafish.
DC12013	NSC45586	A selective protein phosphatase PHLPP inhibitor with IC50 of 4 uM for PP2C domain of PHLPP2.
DC11691	NSC95397	A potent, selective, reversible Cdc25 dual specificity phosphatase inhibitor with Ki of 32/96/40 nM for Cdc25A/B/C, respectively.